{"eventGroups":[{"description":"Participants in this arm were randomized to receive placebo for the first 4 weeks and placebo for the second 4 weeks","id":"EG000","otherNumAffected":1,"otherNumAtRisk":8,"seriousNumAffected":1,"seriousNumAtRisk":8,"title":"Placebo-Placebo"},{"description":"Participants in this arm were randomized to receive placebo for the first 4 weeks and escitalopram for the second 4 weeks","id":"EG001","otherNumAffected":0,"otherNumAtRisk":5,"seriousNumAffected":1,"seriousNumAtRisk":5,"title":"Placebo-Escitalopram"},{"description":"Participants in this arm were randomzied to receive escitalopram for the first 4 weeks and placebo for the second 4 weeks","id":"EG002","otherNumAffected":1,"otherNumAtRisk":11,"seriousNumAffected":0,"seriousNumAtRisk":11,"title":"Escitalopram-Placebo"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"HAM-D score increased by at least 25%"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":5,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":11,"numEvents":0}],"term":"death"}]}